)
Visual
test
FibroBiologics
FibroBiologics (FBLG) investor relations material
FibroBiologics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary24 Feb, 2026
Executive summary
Secured HREC approvals in Australia for a Phase 1/2 trial of CYWC628 in diabetic foot ulcers, enabling enrollment of 120 patients at up to 10 sites.
Filed IND with FDA for CYPS317 in psoriasis and expanded patent portfolio for orthopedic and musculoskeletal therapies.
Raised $7.2M through direct offerings and repaid all outstanding debt.
Received Nasdaq extension to regain compliance for continued listing.
Financial highlights
Research and development expenses rose to $7.4M for 2025, up from $4.5M in 2024, mainly due to higher CRO, lab, and personnel costs.
General and administrative expenses remained flat at $9.2M year-over-year, with shifts in personnel, professional fees, and reduced offering and insurance expenses.
Net loss increased to $18.6M for 2025 from $11.2M in 2024, driven by higher R&D and G&A expenses.
Cash and cash equivalents were $4.9M at year-end 2025.
Outlook and guidance
Plans to complete manufacturing and site enrollment for CYWC628 in Q1 2026, dose first patient and report interim results in H1 2026, and report final results by year-end 2026.
Expects IND clearance for CYPS317 in psoriasis and to submit IND for CYMS101 in multiple sclerosis in H1 2026.
Plans to amend IND for degenerative disc disease by end of 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from FibroBiologics
- All proposals passed, advancing a regenerative medicine pipeline and key share issuances.FBLG
EGM 202620 Feb 2026 - Fibroblast-based therapies show strong preclinical and early clinical promise across multiple indications.FBLGJones Healthcare Seaside Summit 20243 Feb 2026
- Fibroblast therapy advances toward clinical trials, targeting chronic wounds and immune disorders.FBLGMaxim Group’s 2024 Healthcare Virtual Summit19 Jan 2026
- Key votes include a reverse stock split and approval of major new share issuances.FBLGProxy Filing29 Dec 2025
- Board seeks approval for reverse split and stock issuances to maintain Nasdaq listing.FBLGProxy Filing29 Dec 2025
- Registering 22.5M shares for resale, with up to $7.5M in potential proceeds, amid high risk.FBLGRegistration Filing23 Dec 2025
- Proxy seeks approval for reverse split, major stock issuances, and Board-backed governance changes.FBLGProxy Filing18 Dec 2025
- Vote on reverse stock split and warrant share issuances to maintain Nasdaq listing.FBLGProxy Filing18 Dec 2025
- Biotech firm seeks to raise up to $50M for fibroblast-based therapies, led by CEO with voting control.FBLGRegistration Filing16 Dec 2025
Next FibroBiologics earnings date
Q1 20261 May, 2026
FibroBiologics
Next FibroBiologics earnings date
Q1 20261 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage